Feed FBIO
FB

Fortress Biotech, Inc. FBIO NASDAQ · Healthcare · United States

$1.88 -5.53% -$0.11

Summary

64 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 143 USD is left as net profit.
  • It holds more cash than debt: $152.2M against $39.0M.
  • The share price is below the Bulios Fair Price.

What to watch

  • Revenue fell by 5.8% a year over the last 3 years.
  • Its last loss-making year was 2 years ago.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $1.88

By our assumptions the business is worth more than its shares cost today.

P/E today 0.6
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 0.6 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 6.8% a year over 5 years. Over the last 3 years it fell by 5.8% a year.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Biotechnology) -11 USD

Out of every 100 USD of revenue, 143 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $5 is 166% above today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2024

By product

By region

The company reports no revenue by region.

Qbrexza brings in 49% of revenue. Accutane grew fastest, by 25% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy